Strong­bridge rais­es $53M in fi­nanc­ing; Si­en­na Bio sets terms for $70M IPO

→ Strong­bridge Bio­phar­ma has raised $53 mil­lion from CRG. Matthew Pauls, chief ex­ec­u­tive of­fi­cer of Strong­bridge, said: “We ex­e­cut­ed this fi­nanc­ing to trans­form the fi­nan­cial out­look of the Com­pa­ny by ful­ly fund­ing our op­er­at­ing plan un­til we at­tain pos­i­tive cash flow. The funds re­ceived at clos­ing pro­vide suf­fi­cient re­sources for us to build up­on the ear­ly up­take and de­mand that we are see­ing for Keveyis (dichlor­phenamide), and to fund Recor­lev (le­voke­to­cona­zole) through po­ten­tial reg­u­la­to­ry ap­proval and launch.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER